Featured Studies

Researchers at @NIDDKgov are studying new methods in treating thyroid cancer that has spread outside the thyroid – to the lymph nodes, lungs, or bones We are now enrolling patients age 18 years and older with thyroid cancer that spread outside the thyroid. All study tests and procedures are provided at no cost. 

Did you know your thyroid gland produces hormones that regulate body temperature, heart rate and metabolism? Physicians want to explore a better method to detect thyroid tumors by using a compound called 68Gallium-DOTATATE. This compound may bind to a tumor and make it visible during a PET/CT scan. This information will help guide future research and treatment.

Doctors at the National Institutes of Health (NIH) are conducting a research study for thyroid cancer. Researchers are using a novel imaging technique called 68Gallium DOTATATE PET/CT, which has been proven safe and effective in patients with other tumors - neuroendocrine tumors.

Doctors at the National Institutes of Health (NIH) seek patients with thyroid cancer that spread outside the thyroid - to the lymph nodes, lungs or bones. The standard treatment in such situation is therapy with radioactive iodine (RAI). In this study, doctors will assess a new imaging tool - 124I PET/CT, which enables evaluation of how much iodine goes into the tumor. The study goal is to compare how much iodine goes into cancer cells after two different methods of stimulation of RAI uptake.

Women diagnosed with polycystic ovary syndrome (PCOS) needed for a research study at the National Institutes of Health (NIH). Researchers want to learn more about how a medication may be used to help your body's insulin work better and if this can improve your overall metabolic health.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is conducting a pilot intervention study for patients diagnosed with idiopathic membranous nephropathy. The purpose of this study is to evaluate the safety and effectiveness of Rituximab plus Cyclosporine in the treatment of membranous nephropathy. There is no cost for study-related medications or tests received.

Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer.

Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer. (En español)